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Abstract
Introduction Medroxyprogesterone acetate (MPA) induces
estrogen receptor (ER)-positive and progesterone receptor
(PR)-positive ductal invasive mammary carcinomas in BALB/c
mice. We sought to reproduce this MPA cancer model in
C57BL/6 mice because of their widespread use in genetic
engineering. Within this experimental setting, we studied the
carcinogenic effects of MPA, the morphologic changes in
mammary glands that are induced by MPA and progesterone,
and the levels of ER and PR expression in MPA-treated and
progesterone-treated mammary glands. Finally, we evaluated
whether the differences found between BALB/c and C57BL/6
mouse strains were due to intrinsic differences in epithelial cells.
Methods The carcinogenic effect of MPA was evaluated in
C57BL/6 mice using protocols proven to be carcinogenic in
BALB/c mice. In addition, BALB/c and C57BL/6 females were
treated with progesterone or MPA for 1 or 2 months, and
mammary glands were excised for histologic studies and for
immunohistochemical and Western blot evaluation of ER and
PR. Hormone levels were determined by radioimmunoassay.
Isolated mammary epithelial cells were transplanted into cleared
fat pads of 21-day-old female Swiss nu/nu mice or control
congenic animals.
Results MPA failed to induce mammary carcinomas or
significant morphologic changes in the mammary glands of
C57BL/6 mice. The expression of ER-α and PR isoform A in
virgin mice was surprisingly much higher in BALB/c than in
C57BL/6 mammary glands, and both receptors were
downregulated in progestin-treated BALB/c mice (P < 0.05).
PR isoform B levels were low in virgin control mice and
increased after progestin treatment in both strains. ER-β
expression followed a similar trend. No differences in hormone
levels were found between strains. Surprisingly, the
transplantation of the epithelial mammary gland cells of both
strains into the cleared fat pads of Swiss (nu/nu) mice abolished
the mammary gland morphologic differences and the ER and PR
differences between strains.
Conclusion C57BL/6 mammary glands are resistant to MPA-
induced carcinogenesis and to hormone action. MPA and
progesterone have different effects on mammary glands. Low
ER-α and PR-A levels in untreated mammary glands may be
associated with a low-risk breast cancer profile. Although we
cannot at this time rule out the participation of other, untested
factors, our findings implicate the stroma as playing a crucial
role in the strain-specific differential hormone receptor
expression and hormone responsiveness.Page 1 of 16
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ANOVA = analysis of variance; E2 = 17β-estradiol; EGF = epidermal grwoth factor; ER = estrogen receptor; IGF = insulin-like growth factor; MPA = 
medroxyprogesterone acetate; MMTV = murine mammary tumor virus; NIDDK = National Institute of Diabetes and Digestive and Kidney Diseases; 
PBST = phosphate-buffered saline-Tween; PCR = polymerase chain reaction; PR = progesterone receptor;
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Breast cancer is the most common malignancy diagnosed
among women worldwide, and it is the second leading cause
of cancer mortality [1]. One of the hallmarks of the disease is
the expression of estrogen receptor (ER) and progesterone
receptor (PR), and it is this expression that ultimately drives
prognosis and treatment approaches.
During the past 50 years, the experimental study of breast can-
cer has been approached utilizing many different in vivo as
well as in vitro models, some of which have been used widely
[2,3]: the 9,10-dimethyl-1,2-benzanthracene [4,5] and N-
methyl-N-nitrosourea induced mammary tumors in rats [6];
mouse mammary tumor virus (MMTV)-induced carcinomas [7];
human breast cancer cell lines growing in cell culture [8-11] or
as xenografts [12]; transgenic and knockout animals [13,14];
and, more recently, conditional knockout and inducible trans-
genic mice [15]. Genetically engineered mice have been used
extensively to model human breast cancer as well as to dissect
the molecular pathways of tumorigenesis [16], and they have
contributed much to our understanding of how cancer evolves.
Interestingly, most of the genetically modified mice available
for the study of breast cancer do not express ER and PR [2],
leaving few models available in which to address hormone-
dependent tumor progression specifically.
Medroxyprogesterone acetate (MPA) induces ductal mam-
mary carcinomas in BALB/c mice that express ER and PR
[17,18]. During preliminary studies, conducted to investigate
strains that may be susceptible to MPA other than BALB/c, we
found C57BL/6 to be resistant to the standard MPA dosage
that is used to develop mammary carcinomas. This strain had
already been reported to be resistant to mammary tumorigen-
esis induced by MMTV [7], urethane [19] and γ radiation
[20,21]. Interestingly, however, most of the genetically modi-
fied mammary tumor models have been developed in a
C57BL/6 or FVB background [16], without any previous
experimental evidence to indicate that these strains were suit-
able for the study of mammary tumorigenesis, in terms of sus-
ceptibility to the more standard hormonal/chemical
approaches.
With this in mind, we decided to study further the resistance
of the C57BL/6 strain to hormonal carcinogenesis, and to
advance the characterization of possible underlying differ-
ences in hormone responsiveness. In this study we demon-
strated that C57BL/6 mammary glands are resistant not only
to MPA carcinogenesis but also to hormone-induced mam-
mary gland development. The higher responsiveness of BALB/
c mice was associated with higher levels of expression of ER-
α and PR isoform A, suggesting that a high ER-α and PR-A
profile may be related to breast cancer susceptibility. Finally,
we were able to demonstrate that this specific strain differ-
ence disappeared when epithelial cells of either strain were
transplanted into a different strain background, indicating that




Two month-old virgin female BALB/c mice (Instituto de
Biología y Medicina Experimental, Buenos Aires, Argentina)
and C57BL/6J mice (Instituto de Biología y Medicina Experi-
mental and Academia Nacional de Medicina, Buenos Aires,
Argentina) were used for these experiments, and Swiss-
Foxn1nu/Foxn1nu (nu/nu) were purchased from La Plata Ani-
mal Facilities (Buenos Aires Province, Argentina). The animals
were housed in groups of four per cage in an air-conditioned
room at 20 ± 2°C under a 12-hour light/dark cycle, and given
free access to food and tap water. Animal care and manipula-
tion were in agreement with institutional guidelines and with
the Guide for the Care and Use of Laboratory Animals [22].
Athymic nude mice were maintained under the same condi-
tions in a germ-free environment.
Tumor incidence: long-term experiments
Experiment 1
This experiment, conducted in C57BL/6 mice, was performed
simultaneously with previously reported experiments in BALB/
c mice, applying the same protocol originally used to induce
mammary carcinomas [23,24]. A total of 38, 2-month-old
mice, were subcutaneously implanted with 40 mg MPA depot
(Medrosterona, Gador Laboratory, Buenos Aires, Argentina)
every 2 months (four times) for 1 year; 31 control animals
received only vehicle. The animals were evaluated twice
weekly to detect the appearance of mammary tumors. This
experiment was terminated after 1 year because of the emer-
gence of severe skin ulcerations in MPA-treated C57BL/6
mice and in some of the control animals. It has been reported
that aged C57BL/6 mice frequently develop spontaneous
ulcerative dermatitis [25].
Experiment 2
To minimize the possibility of development of skin lesions, the
experiment was repeated with a lower MPA dosage, which
also proved to be carcinogenic in BALB/c mice [23]. Silastic
pellets containing 40 mg MPA (Sigma Co, St Louis, MO, ISA)
were implanted subcutaneously in 39 virgin, 2-month-old,
C57BL/6 female mice, and replaced 6 months later; an equal
number of control animals were implanted with control blank
silastic pellets. The mice were evaluated daily, and those that
developed skin lesions were isolated to prevent further dam-
age, but continued to be evaluated as part of the experiment.
The animals were weighed every week and followed for 14
months. Vaginal smears were obtained from selected mice in
control and MPA-treated groups to confirm hormone action.
After 6 months, MPA-treated mice started to cycle again and
MPA pellets were replaced. Every 2 months two mice from
both groups were killed for histologic evaluation of mammary
gland hormone responsiveness. At the end of the experimentsPage 2 of 16
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glands fixed in formalin (right 4th gland), prepared for whole
mounts (left 4th gland), or frozen for Western blot studies.
Short-term experiments
Mammary gland and salivary gland morphologic studies
A total of 24 BALB/c and 24 C57BL/6 virgin females (2-
month-old) were implanted subcutaneously with 20 mg MPA,
progesterone (Sigma Co.), or control blank silastic pellets
(four mice per group). After 4 or 8 weeks the animals were
killed, and salivary glands and the 4th right mammary glands
were fixed in formalin and embedded in paraffin. Left mammary
glands were processed for whole mounts. This experiment
was repeated twice. Control animals were killed at diestrus.
The morphologic features and the number of ducts, lateral
branches, and lobules of the mammary glands of virgin
untreated and progestin-treated mice were evaluated in hema-
toxylin and eosin stained slides and quantified in 40× fields.
Whole mount studies
The mammary glands were excised together with the attached
skin, stretched and pinned down to a cork slab, and fixed in
10% buffered formalin for 24 hours. After fixation, the glands
were dissected and extensively washed with distilled water,
and lipids were removed by immersing in acetone for 2 days,
at room temperature. After hydration with decreasing concen-
trations of ethanol, the tissues were left overnight in water and
stained with toluidine blue (0.025% in water) for 40 min fol-
lowed by thorough washings with distilled water. The staining
was adjusted by destaining, if necessary, with methanol for 30
min and 70% ethanol for other 30 min, under microscopic
observation. After washing with distilled water the tissues
were fixed in ammonium molybdate for 30 min, washed again,
dehydrated in ethanol with increasing concentrations, and
transferred to xylene overnight before mounting.
Immunohistochemistry
Paraffin-embedded sections were reacted with various anti-
bodies using the avidin biotin peroxidase complex technique
(Vectastain Elite ABC kit; Vector Laboratories, Burlingame,
CA, USA). Briefly, after dewaxing and hydrating, endogenous
peroxidase activity was inhibited using 3% H2O2 in distilled
water. Blocking solution (2% normal goat serum) was used
before specific antibody. Polyclonal antibodies to ER-α (MC-
20; Santa Cruz Biotechnology, Santa Cruz, CA, USA), ER-β
(chicken antibody kindly provided by Jan-Åke Gustafsson,
Karolinska Institutet, Novum, Sweden), and PR A (C-20; Santa
Cruz Biotechnology) and the monoclonal antibody to PR-B
(Ab 6; Neomarkers, Union City, CA) were used at 1:100 dilu-
tion and incubated overnight at 4°C. After incubation with the
appropriate secondary antibodies (Vector Laboratories) the
reactions were developed with 3-3'diaminobenzidine 0.30%
in phosphate-buffered saline with H2O2 to a final concentra-
tion of 0.5%, under microscopic control. Specimens were
counterstained with hematoxylin, dehydrated, and mounted.
To quantify ER and PR, 1500 epithelial cells per slide were
counted.
Western blots
Mammary glands were homogenized with a polytron at setting
50 with three bursts of 5 s at a 1:4 ratio of tissue to TEDGS
(50 mmol/l Tris [pH 7.4], 7.5 mmol/l EDTA, 0.5 mmol/l dithio-
threitol, 10% glycerol, and 0.25 mol/l sucrose) buffer. Pro-
tease inhibitors [0.5 mmol/l phenylmethylsulfonylfluoride
(PMSF), 0.025 mmol/l CBZ-L-phenylalanine choromethylke-
tone (ZPCK), 0.0025 mmol/l N-alpha-p-tosyl-L-lysine choro-
methylketone (TLCK), 0.025 mmol/l N-alpha-p-tosyl-L-pheny-
lalaninechlomethylketone (TPCK), 0.025 mmol/l N-alpha-p-
tosyl-L-argininemethylester (TAME)] were added before pre-
paring the extracts. The homogenate was centrifuged for 10
min at 3,300 rpm at 4°C, and the nuclei on the pellet were
washed in TEDGS buffer plus 0.01% NP-40. The nuclei were
resuspended in TEDGS containing 0.4 mol/l KCl and incu-
bated at 4°C for 30 min, and the nuclear homogenate was
centrifuged at 12,000 rpm for 20 min at 4°C. The nuclear
extract was diluted 1:2 in TEDGS buffer with 30% glycerol, to
reduce the salt concentration. Proteins were quantified using
the method proposed by Lowry and coworkers [26].
The samples (100 μg total protein/lane) were separated on
8% (PR) or 10% (ER) discontinuous polyacrylamide gels
(SDS-PAGE) using Laemmli's buffer system [27]. The pro-
teins were dissolved in sample buffer (6 mmol/l Tris [pH 6.8],
2% SDS, 0.002% bromophenol blue, 20% glycerol, and 5%
mercaptoethanol) and boiled for 4 min. After electrophoresis,
they were blotted onto a nitrocellulose membrane and blocked
overnight in 5% dry skimmed milk dissolved in phosphate-buff-
ered saline-Tween (PBST) 0.1% (0.8% NaCl, 0.02% KCl,
0.144% Na2PO4, 0.024% KH2PO4 [pH 7.4], 0.1% Tween
20). The membranes were washed several times with PBST
and then incubated with PR Ab-7/hPRa 7 (Ab7; Neomarkers,
Union City, CA, USA) or C-19 (Santa Cruz), ER-α (MC-20;
Santa Cruz), or actin (clone ACTN05; Neomarkers) at room
temperature for 2 hours, at a concentration of 2 μg/ml in
PBST. Blots were probed with sheep anti-mouse or donkey
anti-rabbit immunoglobulin, horseradish peroxidase-conju-
gated whole antibody (Amersham Life Science, Buckingham-
shire, UK). The luminescent signal was generated with the
ECL Western blotting detection reagent kit (Amersham Phar-
macia Biotech, Buckinghamshire, UK), and the blots were
exposed to medical X-ray film (Curix RP1; Agfa Argentina, Flor-
encio Varela, Buenos Aires) for 10 s to 5 min. Band intensity
was not quantified if the film was saturated.
Effect of 17β-estradiol on mammary gland development
Four BALB/c and four C57BL/6 mice were implanted with 20
μg 17β-estradiol (E2) pellets, or E2 plus 20 mg MPA, or pro-
gesterone, and killed after 2 months. Mammary glands were
processed as described above for morphologic studies.Page 3 of 16
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BALB/c (n = 28) and C57BL/6 (n = 27), 2-month-old female
mice were implanted subcutaneously with control blank silas-
tic, MPA (40 mg), or progesterone (40 mg) pellets, and after
24 hours the animals were bled by retrorbital puncture under
anesthesia. Control mice were bled at diestrus, as evaluated
by vaginal smears. Prolactin and growth hormone were meas-
ured by radioimmunoassay using a kit provided by the National
Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK; Dr AF Parlow, National Hormone and Pituitary Pro-
gram, Torrance, CA, USA). The assays were performed using
10 μl serum samples in duplicate, and the results were
expressed in terms of the reference preparation of mouse pro-
lactin NIDDK-RP3 and mouse growth hormone AFP-107836
standards, respectively. Intra-assay and interassay coefficients
of variation were 7.2% and 12.8%, and 8.4% and 13.2%,
respectively [28]. For insulin-like growth factor (IGF)-I radioim-
munoassay, serum samples (15 μl) and IGF-I standards were
subjected to the acid-ethanol cryoprecipitation method, as
previously described [28]. IGF-I was determined using an anti-
body (UB2-495) provided by Drs L Underwood and JJ Van
Wyk, and distributed by the Hormone Distribution Program of
the NIDDK. Recombinant human IGF-I (Chiron Corp., Emery-
ville, CA, USA) was used as radioligand and unlabeled ligand.
The assay sensitivity was 6 pg per tube. Intra-assay and inte-
rassay coefficients of variation were 8.2% and 14.1%, respec-
tively. Progesterone was determined by radioimmunoassay
using an antibody kindly provided by Dr GD Niswender (Colo-
rado State University, Fort Collins, CO, USA), and labeled hor-
mone (progesterone [1,2,6,7 3H(N)]) was purchased from
Dupont NEN, Boston, MA, USA. Assay sensitivity was 50 pg,
and intra and interassay coefficients of variance were 7.5 and
11.9%, respectively.
Transplantation of BALB/c or C57BL/6 epithelial mammary 
cells into cleared fat pads from Swiss nude mice
Mammary glands from six C57BL/6 and six BALB/c 2-month-
old female mice were excised and epithelial cells were isolated
using the same protocol that we routinely use to isolate mam-
mary tumor cells [29]. An equal number of cells (106 in 5 μl)
was inoculated in the right (BALB/c) or left (C57BL/6) cleared
fat pads of 21-day-old female nu/nu mice (Swiss background)
that had previously been implanted subcutaneously with pro-
gesterone (20 mg) or MPA (20 mg) silastic pellet also contain-
ing 20 μg E2; four animals received blank silastic pellets, and
four animals were used as a control ensuring that no epithelial
cells remained after clearing the fat pads. The mammary
glands were cleared according to standardized protocols
[30,31]. Four BALB/c and four C57BL/6 mice were also used
as control animals. After 30 days, mammary glands were
excised, fixed in 4% buffered formaldehyde, and prepared for
histologic evaluation. The experiment was repeated twice. To
capture the entire area of interest, several partially overlapping
high-definition images were taken from each case with a total
magnification of 160×, using a real-time Nikon 1300 digital
camera with the QImaging Pro software (MVIA, Inc., Monaca,
PA, USA). The images were then aligned together using the
PanaVue Image Assembler Software (PanaVue Co., Quebec
City, Quebec, Canada). The resulting image was a high-quality
panoramic picture of the lesion that allowed us to select the
epithelial areas. Images were quantified using the Northern
Eclipse Image Analysis Software (Empix Imaging, North Tona-
wanda, NY, USA) and expressed as the total epithelial area
and the number of structures selected in each histologically
defined area. To determine ER and PR expression in reconsti-
tuted mammary glands, the same procedures were performed
in four untreated Swiss nu/nu mice, BALB/c or C57BL/6
mice.
Laser capture microdissection studies
Four to six 6 μm consecutive sections from normal mammary
gland were obtained from paraffin-embedded tissue, dewaxed
as described above, and stained with hematoxylin and eosin.
Approximately 5 × 103 ductal epithelial cells were then micro-
dissected using a PixCell II LCM system (Arcturus Engineer-
ing, Mountain View, CA, USA). Briefly, the cap was inserted
into an Eppendorf tube containing digestion buffer (50 μl
buffer containing 0.04% Proteinase K*, 10 mmol/l Tris-HCL
[pH 8.0], 1 mmol/l EDTA, and 1% Tween-20). The tube was
placed in an oven at 37°C to equilibrate and then placed
upside down so that the digestion buffer contacts the tissue
on the cap. The incubation continued overnight at 37°C and
was then centrifuged for 5 min and the cap removed. The reac-
tion was heated to 95°C for 8 min to inactivate the proteinase
K. Samples were purified by means of the DNeasy Tissue Sys-
tem kit (Qiagen, Chatsworth, CA, USA) before PCR. We per-
formed tests of the DNA samples by PCR amplifications with
four informative microsatellite markers.
Microsatellite genotyping
Epithelial DNA was typed by PCR using a panel of four micro-
satellites (also known as simple sequence length polymor-
phisms) polymorphic between C57BL/6 and the outbred
Swiss recipient nude females. The simple sequence length
polymorphism primers (Mouse MapPairs) were purchased
from Invitrogen (Carlsbad, CA, USA). An aliquot of 100 ng
genomic DNA (5 μl of 20 ng/μl) was amplified in a 25 μl PCR
reaction containing 2.5 μl 10× PCR buffer (15 mmol/l MgCl2),
0.5 μl 10 mmol/l dNTP, 1 μl of each primer (final concentration
180 μmol/l), 0.1 μl 5 U/μl Taq polymerase, and 14.9 μl sterile
water. Hot start PCR (in which crucial reaction components
are withheld until reaction temperatures are reached) was per-
formed by means of FastStart Taq polymerase (Roche, Indian-
apolis, IN, USA). Initial denaturation (94°C for 6 min), 35
cycles (45 s at 94°C, 45 s at 55°C, and 30 s at 72°C), and
final incubation at 72°C for 7 min were carried out using a Per-
kin-Elmer Model 9600 DNA thermal cycler (Applied Biosys-
tems, Foster City, CA, USA). PCR products were separated
by electrophoresis in 4% agarose gels, and stained with 0.5
μg/ml ethidium bromide.Page 4 of 16
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Differences between groups in the number of structures and
stained nuclei were evaluated using analysis of variance
(ANOVA) followed by the Tukey t-test to compare differences
between experimental and control groups. To compare differ-
ences in body weight or prolactin, growth hormone, IGF-I, or
progesterone serum levels between progestin-treated and
untreated mice, a two-way ANOVA was used. The actuarial
incidence of mammary tumor was calculated according to
Kaplan-Meier distributions and log rank tests as described
previously [23], and differences in tumor incidences were eval-
uated using χ2 tests.
Results
Long term in vivo experiments
Tumor incidence
From a total of 47 BALB/c mice initially treated with MPA, 34
developed ductal infiltrating carcinomas, from which 13 arose
during the first 12 months (27.6%). The mean latency was 52
weeks, and no mammary tumors were observed in untreated
control animals [24]. MPA-treated C57BL/6 female mice did
not develop mammary tumors, and neither did the control
untreated animals (treated BALB/c versus treated C57BL/6
for 1 year; P < 0.001; data not shown). C57BL/6 mice treated
with MPA developed severe skin ulcerations, and this arm of
the experiment had to be stopped after a year.
In a second experiment, only C57BL/6 mice were treated
using a protocol that had also proven to be carcinogenic in
BALB/c animals, consisting of implanting 40 mg MPA pellets
at the beginning of the experiment and replacing them after 6
months [23]. None of the animals in this group developed any
mammary lesions, and after 14 months the experiment was ter-
minated (Figure 1a).
Figure 1
Tumor incidence, mammary gland alterations and body weight curves in MPA-treated mice. (a) Mammary tumor incidence. C57BL/6 mice were 
implanted with 40 mg MPA pellets that were replaced 6 months later; historical values of BALB/c using the same protocol were included for com-
parison. No mammary tumors appeared in MPA-treated or control C57BL/6 mice; control mice were implanted subcutaneously with silastic pellets. 
(b) Mammary gland alterations in MPA-treated BALB/c and C57BL/6 mice after one year of MPA treatment. The subpanels show the following: (a) 
a distorted and rotated ductal structure that appears to be forcibly stretched in areas (WM); (b) hyperplasia in the form of irregular paraductal prolif-
eration (WM); (c) atypical ductal side branching showing areas of neoplastic growth (arrows; WM); (d) hematoxylin and eosin showing ductal hyper-
plasia; (e,f) WM and hematoxylin and eosin pictures showing nearly normal mammary glands of MPA-treated C57BL/6 mice; and (g,h) WM and 
hematoxylin and eosin pictures of C57BL/6 control mice. (c) Body weight curves of C57BL/6 mice implanted with 40 mg MPA (first arrow) or con-
trol blank silastic pellets that were replaced after 6 months (second arrow). All animals were weighed weekly and the results expressed as mean ± 
standard error. MPA-treated animals showed an increase in body weight that was already evident after the second week of treatment (P < 0.001; 
two-way ANOVA). ANOVA analysis of variance; MPA, medroxyprogesterone acetate; WM, whole mount.Page 5 of 16
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MPA induces proliferative ductal lesions in BALB/c mice that
are characterized by preneoplastic intraductal solid, papillary,
or cribiform growth associated with an intense stromal reac-
tion, with periductal fibrosis, an increase in mammary connec-
tive tissue, and moderate to intense mononuclear infiltration
[32]. In whole mount studies, mammary glands from MPA-
treated animals exhibited a gross distortion of the mammary
gland architecture and developed hyperplasia in the form of
paraductal branching (Figure 1b, top). Ductal hyperplasia was
also a common finding. None of these lesions were observed
in C57BL/6 MPA-treated mice (Figure 1b, bottom).
Effect of MPA on body weight
We previously observed a significant anabolic effect of MPA
on the body weight of BALB/c mice [33,34] and, as shown in
this study, a similar effect was observed in C57BL/6 mice (Fig-
ure 1c; two-way ANOVA, P < 0.001).
Short term experiments
Mammary gland morphology
To evaluate early morphologic responses to MPA or proges-
terone on the mammary gland, C57BL/6 and BALB/c mice
were treated with MPA or progesterone, or implanted with
blank silastic pellets for 4 or 8 weeks, after which the animals
were killed and the mammary glands excised and processed
for whole mount or hematoxylin and eosin studies. When
untreated mammary glands from control virgin mice of both
strains, without any treatment and in the same phase of the
estrous cycle, were compared, BALB/c untreated mammary
glands exhibited more ductal side branching than did C57BL/
6 glands (Figure 2a,b, left panels), and only BALB/c mice
exhibited a significant increase in MPA-induced ductal branch-
ing in mammary glands (Figure 2a,b, middle panels; P <
0.001). The effect of progesterone was different from that of
MPA; lobular differentiation was observed in both strains,
although the effect in BALB/c mice was more prominent (Fig-
ures 2a,b, right panels). Quantification of these morphologic
differences is shown in Figure 2c. These experiments confirm
that MPA and progesterone have different effects in C57BL/6
and BALB/c animals, with significantly lower hormone respon-
siveness in the C57BL/6 strain.
Hormone receptors
All receptors were evaluated by immunohistochemistry using
validated antibodies [35-38]. The number of positive cells was
expressed as the percentage of stained nuclei per number of
epithelial cells/400× fields. There were significant differences
in the number of ER-α-positive cells between virgin mammary
glands of both strains (41.2 ± 10% in BALB/c versus 19 ±
7.5% in C57BL/6 mice; P < 0.001; Figures 3a and 4c). MPA
treatment resulted in a significant decrease in ER-α expression
only in BALB/c mice (Figure 3a; P < 0.05). ER-β expression
was low in control virgin mice of both strains (Figures 3b and
4c) that increased in MPA (P < 0.05) and in progesterone-
treated BALB/c animals (P < 0.001; Figure 3b) but not in
C57BL/6 mice.
The pattern of PR-A expression was very similar to that of ER-
α; again, significantly higher levels were observed in untreated
BALB/c mice (Figure 4a,c), which were more efficiently down-
regulated by MPA (P < 0.001) than by progesterone (P <
0.05; Figure 5a). Virgin untreated mice of both strains exhibit
almost no PR-B expression, as previously reported [35] (Fig-
ures 4b,c). Interestingly, PR-B was highly expressed in MPA
and progesterone treated BALB/c (P < 0.001 and P < 0.05,
respectively) and C57BL/6 mice (P < 0.01; Figure 4b), and
followed a similar pattern of expression as ER-β.
Nuclear extracts from progestin-treated or virgin control mice
were used for Western blots (Figure 5a). Extracts were nor-
malized by protein content. Because mammary glands from vir-
gin mice have less epithelial cells than progestin-treated mice,
and on the other hand both stroma and epithelium may
express steroid receptors, which may be differentially regu-
lated, we only quantified the ratio between both isoforms in the
same blot (Figure 5b). The PR-A/PR-B ratio was significantly
higher in virgin as compared with progestin treated mice of
both strains, supporting the immunohistochemical data. In
addition, virgin BALB/c mammary glands expressed higher
levels of PR-A and ER-α (data not shown) than did C57BL/6
glands (P < 0.01). Significant differences between MPA and
progesterone treatment were not detected in Western blots.
Progestin effect on salivary gland morphology
MPA, because of its androgenic action [39], has a specific
effect on salivary gland morphology in that it induces the devel-
opment of convoluted granular ducts [24], which was
observed in both strains (Figure 6a). Progesterone had no
notable effects on salivary glands.
Serum prolactin, growth hormone, progesteron, and insulin-
like growth factor-I levels
ER knockout mice develop a hypoplastic mammary gland phe-
notype as a consequence of a pituitary gland dysfunction
associated with a decrease in prolactin levels [40]. To explore
the possibility of pituitary dysfunction as an explanation for the
strain differences in hormone responsiveness, we evaluated
serum levels of prolactin in control and progestin-treated mice,
but we failed to observe any difference between C57BL/6 and
BALB/c mice. In addition, prolactin levels were increased in
progestin-treated animals of both strains (P < 0.001, two-way
ANOVA; Figure 6b). Similarly, no differences in progesterone,
growth hormone, or IGF-I levels between strains were
observed. Furthermore, serum levels of progesterone reached
after the implantation of 20 mg progesterone pellets was also
similar in both strains (Figure 6b).Page 6 of 16
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To further explore whether the responsiveness of this strain
was related to differences in the epithelial mammary cells or in
the stromal environment, we transplanted the epithelial
mammary cells into nu/nu mice of a different strain back-
ground. Because nude mice lack functional ovaries and con-
sequently have very low E2 levels, this hormone had to be
supplemented (20 μg) to the MPA or progesterone standard
pellets. Therefore, we first evaluated whether the differences
between strains were also observed when E2 or combined E2
and progesterone pellets were used. The differences were sig-
nificant, even with E2 alone (Figure 7). E2 induced duct dilation
whereas the combined treatment induced a high proliferative
response, with increased branching and lobule-alveolar differ-
entiation. Surprisingly, however, C57BL/6 cells were able to
repopulate the cleared fat pads of MPA/E2-treated or proges-
terone/E2-treated Swiss nu/nu mice as efficiently as BALB/c
Figure 2
Mammary glands from progestin-treated micei . MPA (40 mg), Pg (40 mg), or control blank silastic pellets were implanted subcutaneously in 2-month-
old (a) BALB/c or (b) C57BL/6 female mice. After 2 months, the mice were killed and the mammary glands processed for histological evaluation 
(H&E) or for WM (as described in the Materials and methods section). A representative image observed in at least four different mice of each group 
is presented. The numbers of ducts (black arrow), lobules (white arrow), and lateral branching (dotted arrow) were (c) quantified in each H&E 
stained slide and expressed as the number of structures per 400× field. MPA treatment induced an increase in the number of ducts and in lateral 
branching only in BALB/c mice, whereas Pg induced an increase in the number of lobules mainly in BALB/c. In control groups, animals were eutha-
nized at diestrus. ***P < 0.001, treated versus control; aP < 0.05 between controls of both strains. Magnification: 100×, bar: 100 μm. H&E, hema-
toxylin and eosin; MPA, medroxyprogesterone acetate; Pg, progesterone; WM, whole mount.Page 7 of 16
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repopulating BALB/c cleared fat pads than did C57BL/6 cells
in C57BL/6 cleared fat pads.
To confirm that the transplanted cells were those giving rise to
the mammary glands and not some pre-existing epithelial cells
from the recipient Swiss nu/nu female, ducts and lobules were
excised by laser capture microdissection and genotyped by
PCR using four informative microsatellite markers (D7Mit69,
D7Mit82, D10Mit233, and D13Mit7). These markers were
selected to be polymorphic between C57BL/6 and the recip-
ient nude females. The PCR analysis clearly showed that the
Figure 3
ER expression in mammary glands treated with progestins for 2 months. For both (a) ER-α and (b) ER-β, a representative image of four to 10 histo-
logical slides/group is shown. The number of stained cells was quantified and expressed as a percentage of the number of stained cells among epi-
thelial cells in 400× fields of every slide (bar: 80 μm). A minimum of 1,500 epithelial cells/slide were counted. The right panels show the 
quantification in control (filled columns), MPA-treated (dotted columns), and Pg-treated (empty columns) mice (mean ± standard error). ER-α was 
significantly lower in C57BL/6 mice (P < 0.001), and there was a significant decrease with MPA treatment in BALB/c mice. Regarding ER-β, there 
was a significant increase in progestin-treated BALB/c mice. In control groups, animals were killed at diestrus; animals were treated for 2 months. *P 
< 0.05, ***P < 0.001 control versus treated mice. ER, estrogen receptor; MPA, medroxyprogesterone acetate; Pg, progesterone.Page 8 of 16
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PR expression in mammary glands treated with progestins for 2 months: immunohistochemical studies. Control mice received blank silastic pellets. 
For both (a) PR-A and (b) PR-B, a representative image of four to six histologic slides per group is shown. The number of stained cells is expressed 
as the percentage of the number of stained cells per epithelial cells in 400× fields of every slide and a minimum of 1,500 epithelial cells/slide were 
counted (bar: 80 μm). The right panels show the quantification in control (filled columns), MPA-treated (dotted columns), and Pg-treated (empty col-
umns) mice (mean ± standard error). PR-A expression decreased significantly in progestin-treated BALB/c mice, whereas PR-B expression 
increased in progestin-treated mice of both strains. *P < 0.05, **P < 0.01, ***P < 0.001 control versus treated mice. (c) Quantification (mean ± 
standard error) of the percentage of positive stained cells for ER-α, ER-β, PR-A, and PR-B in control BALB/c or C57BL/6 female mice shown in Fig-
ures 3 and 4a,b. BALB/c mice show higher levels of ER-α and PR-A than C57BL/6 female mice. In control groups, animals were killed at diestrus. 
***P < 0.001, **P < 0.01. ER, estrogen receptor; MPA, medroxyprogesterone acetate; Pg, progesterone; PR, progesterone receptor.Page 9 of 16
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microdissection were C57BL/6 in origin (Figure 8). These
results indicate that strain-specific host factors probably mod-
ulate mammary epithelial hormone responsiveness.
ER and PR expression in recombined mammary glands in 
nu/nu mice
We were now interested in determining whether the differ-
ences in ER-α and PR-A expression observed between both
strains would even out when epithelial mammary cells from
both strains were inoculated in the same host. Because the
differences were evident only in untreated animals, we per-
formed the same recombination experiments in untreated
mice. Figure 9 shows ducts that originated from C57BL/6 or
BALB/c cells transplanted in the same nu/nu mouse; no sig-
nificant differences in ER-α or PR-A expression were
observed. These results indicate that host factors are respon-
sible for the strain differences observed in mammary gland
hormone receptor expression and that the level of these recep-
tors is related to the degree of hormone responsiveness.
Discussion
The C57BL/6 strain is reputed to be relatively resistant to
some chemical carcinogenesis protocols [41-43] and rela-
tively susceptible to spontaneous and chemically induced
melanomas [44], radiation-induced leukemia [45], and chemi-
cally induced urinary bladder carcinomas [46]. Regarding
mammary tumorigenesis, the C57BL/6 strain is considered to
be resistant to MMTV [7], urethane [47], and γ radiation
[20,21].
In this study we demonstrated that C57BL/6 female mice
were resistant to MPA-induced carcinogenesis, and that this
resistance was associated with poor mammary gland respon-
siveness to the exogenous administration of progestins and/or
estrogens. We also observed significantly different levels of
ER-α and PR-A in the sensitive and resistant strains, that may
be associated with the poor responsiveness described. Sur-
prisingly, C57BL/6 mammary epithelial cells may be as
responsive as BALB/c cells and exhibit similar levels of hor-
mone receptors when transplanted into cleared fat pads of a
different strain, indicating that host factors rather than the epi-
thelial cells by themselves are responsible for their hormone
resistance.
A hypoplastic phenotype of C57BL/6 mammary glands was
reported by Nandi and Bern in 1960 [48]. In most of their
experiments, hormonal treatment was provided by the kidney
subcapsular implantation of the pituitary gland, or by the
administration of estrogens or combinations of estrogens plus
progesterone; the effects of progestins alone, however, have
been evaluated in very few studies [23,49]. Our findings dem-
onstrate a differential effect of progestins in BALB/c and
C57BL/6 female mice and confirm the observations by Nandi
and Bern regarding differences in mammary glands of virgin
mice. MPA induced ductal branching whereas progesterone
induced lobular differentiation in BALB/c and not in C57BL/6
mice. These observations correlate with the fact that MPA
induced mainly ductal carcinomas whereas progesterone gen-
erated mainly lobular carcinomas in BALB/c mice [23]. These
tumors are different not only in histology but also in ER, PR,
and epidermal growth factor (EGF) receptor expression [24].
Recent studies indicate that progesterone and MPA trigger
different transduction signals in the human breast cancer cell
line T47D [50] and in human umbilical vein endothelial cells
[51]. Different in vivo effects were also reported in previous
studies, in which it was observed that MPA induced the syn-
thesis of EGF in salivary glands as an androgen receptor lig-
and [39,52]. This effect was not achieved by progesterone. As
we have demonstrated in previous studies, salivary gland EGF
Figure 5
PR expression in mammary glands treated with progestins for 2 months: Western blot studies
months: Western blot studies. Mammary glands from the same groups 
shown in Figure 4 were processed to obtain nuclear extracts (as 
explained in Materials and methods) and used in Western blots. (a) A 
representative experiment using C-19 PR Santa Cruz antibody is 
shown. Because different amounts of epithelial cells are present in the 
different extracts, the (b) ratio of PR-A/PR-B in three different experi-
ments is shown. *P < 0.05, **P < 0.01, ***P < 0.001 treated versus 
control. PR, progesterone receptor.Page 10 of 16
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carcinogenesis [24,53]. Because C57BL/6 mammary glands
responded poorly to both MPA and progesterone, it seemed
unlikely that the differences in the two strains were related to
differences in salivary gland responsiveness. This was sup-
ported by the fact that no histologic differences with respect
to MPA-induced development of convoluted granular ducts of
the salivary glands, the source of EGF, were found across
strains. MPA has been used as an anabolic agent in oncology
[54] and, as we have shown in previous studies, it exerts an
anabolic effect in BALB/c female mice [33]. In the present
study we demonstrated a similar effect in C57BL/6 mice,
showing that this is a strain-independent mechanism.
We have also explored the possibility of impaired pituitary
function, which plays a very important role in determining the
hypoplastic mammary gland phenotype in ER knockout mice
[40], and is associated with low prolactin levels. However, in
our study, prolactin levels were similar in C57BL/6 and BALB/
c mice and in progestin-treated animals of both strains. The
same was true for progesterone, growth hormone, and IGF-I
serum levels.
Figure 6
Effects of progestins in salivary gland morphology and in serum pituitary hormone levelsi  it it r  r  l l . (a) Salivary glands from control, MPA, or Pg-treated BALB/
c or C57BL/6 mice. Pellets were implanted subcutaneously and the animals killed after 2 months. MPA increased the development of convoluted 
granular ducts (arrow). No differences were observed between both strains of mice (400×, bar: 120 μm). (b) Serum PRL, Pg, GH, and IGF-I levels 
measured by radioimmunoassay in control BALB/c or C57BL/6 female mice and after 24 hours of MPA or Pg treatment. No differences were 
detected in C57BL/6 mice as compared with BALB/c mice. Furthermore, Pg and MPA treatment induced an increase in PRL levels in both strains 
(P < 0.001, two-way ANOVA). The increase in Pg levels after progesterone administration was also similar in both strains (P < 0.001, two-way 
ANOVA). Gray bars: BALB/c; black bars: C57BL/6. ANOVA, analysis of variance; GH, growth hormone; IGF, insulin-like growth factor; MPA, 
medroxyprogesterone acetate; Pg, progesterone; PR, progesterone receptor; PRL, prolactin.Page 11 of 16
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to strain differences intrinsic to the mammary gland. To explore
this possibility, we sought to determine the presence and func-
tionality of mammary steroid receptors in both strains. To eval-
uate PR A, we used C-19 and C-20 antibodies (Santa Cruz)
that recognize this isoform in human tissues [55] and mouse
tissues [35,38]. We observed significantly lower levels of ER-
α and PR-A in virgin C57BL/6 adult female mice, as compared
with BALB/c. The only PR isoform that we found to be highly
expressed in BALB/c virgin mice was PR-A, as was previously
described by Auperlee and coworkers [35]. PR-A and ER-α
were significantly downregulated in both BALB/c MPA-
treated and progesterone-treated mice, and it is interesting to
note that ER-α expression usually paralleled that of PR-A. ER-
β and PR-B exhibited similar kinetics; their expression was low
in control mice and it increased in progestin-treated BALB/c
mice. Aupperlee and coworkers [35] reported similar results in
their studies of PR-B expression in pregnant BALB/c mice.
These results, when extrapolated to humans, suggest that indi-
vidual levels of ER-α and PR-A in the mammary glands could
predict hormone responsiveness and cancer risk. It has been
reported that low levels of ER-α expression are observed in
women of low risk groups [56,57]. As proof of principle, Frech
and coworkers [58] developed transgenic mice that overex-
press ER-α in a C57BL/6 background, in which the number of
ER-α positive cells in transfected glands was similar to that in
the virgin BALB/c mice we report on here. Curiously, ductal
hyperplasias were reported in the transgenic mice even in the
absence of estrogens. As a consequence of ER-α overexpres-
sion, increased PR levels were also observed.
The expression of ER and PR is regulated by endocrine factors
and by extracellular matrix components such as collagen IV or
laminin [59]. To explore a role for the stroma in the strain dif-
ference in hormone responsiveness, we used transplanted
epithelial cells into the cleared fat pad of Swiss nude mice. The
fact that both C57BL/6 and BALB/c epithelial cells
responded very similarly in a different strain background sug-
gests that the mammary gland fat pad from the host may be
regulating the epithelial hormone responsiveness. At this
moment we cannot, however, rule out the participation in the
process of other host factors related to the microenvironment,
which may be also be playing an active role. Experiments are
currently underway in our laboratory to test this alternative
hypothesis. Similar data were reported by Naylor and
Ormandy [60]. Those investigators recombined epithelial cells
from 129 strain, which is similar to BALB/c, with C57BL/6
stroma, and observed a poorly side-branched C57BL/6 pat-
tern. A major challenge will be to identify the stromal factors
responsible for maintaining high ER and PR-A levels in BALB/
c mice.
Different studies have been designed to explain BALB/c sus-
ceptibility to mammary carcinogenesis. The frequency of mam-
mary tumors differs among strains of Trp53+/- mice, with
mammary tumors occurring only on a BALB/c genetic back-
ground and showing a high frequency of loss of heterozygosity
[61]. Interestingly, progesterone is necessary and favors ane-
uploidy in this model [62]. In the irradiation model, the
increased genomic instability of BALB/c mice has been
ascribed to two polymorphisms in the coding region of Prkdc
[63]; this is the gene that encodes the DNA-dependent pro-
tein kinase catalytic subunit, which is known to be involved in
DNA double-stranded break repair. Because it has been
shown that the stroma may be a target in radiation-induced
[64] and in chemical-induced carcinogenesis [65], other play-
ers important in parenchymal-stromal interactions related with
hormone receptor expression may be involved in all models.
Figure 7
Mammary glands from BALB/c or C57BL/6 mice treated with E2 or E2 plus Pg
plus Pg. Mice were implanted subcutaneously with silastic pellets con-
taining E2 (20 μg) or Pg (20 mg) + E2 (20 μg). Representative H&E 
stained sections and WM are shown. The arrow points to ductal dilata-
tions, typical of E2 action in BALB/c mice. All WM pictures were taken 
at the same magnification. Magnification: 100×, bar: 1.1 μm.P < 0.05, 
BALB/c versus C57BL/6. E2, 17β-estradiol; H&E, hematoxylin and 
eosin; N, number of structures/slide; Pg, progesterone; WM, whole 
mount.Page 12 of 16
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In this study we demonstrated impaired hormone responsive-
ness in C57BL/6 mammary epithelial cells that is reflected in
responses to both physiologic and neoplastic stimuli, making
the strain resistant to hormonal carcinogenesis. This was
associated with low levels of ER-α and PR-A. Further exploring
the phenomenon, we demonstrated that this is not due to
intrinsic impairments in the epithelial cells and that host fac-
tors, probably related to the mammary microenvironment, may
account for the defective hormonal behavior. The comparative
study of C57BL/6 and BALB/c mice may help us to
understand the genetic basis of resistance and susceptibility
to hormone-induced mammary carcinogenesis.
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Figure 8
Morphology of reconstituted mammary glands of both strains into a nude background. Mammary cells were isolated from 2-month-old BALB/c or 
C57BL/6 mice and 5 μl of cell suspensions were transplanted into the right or left cleared mammary fat pads, respectively, of 21-day-old Swiss nu/
nu or syngeneic mice. At surgery pellets containing E2 plus Pg or plus MPA were also implanted subcutneously into the backs of the animals. One 
month later, animals were killed and mammary glands excised and fixed. Microscopic examination revealed no changes between C57BL/6 or BALB/
c repopulated Swiss nu/nu glands, whereas C57BL/6 cells transplanted in syngeneic glands were under-developed (100×, bar: 700 μm). A repre-
sentative image of the WM or the H&E stained slides of the reconstituted mammary glands in E2/Pg-treated mice is shown. Microsatellite studies 
confirmed the strain origin of the epithelial cells in the Swiss background. bp, base pairs; E2, 17β-estradiol; H&E, hematoxylin and eosin; LCM, laser 
capture microdissection; MPA, medroxyprogesterone acetate; Pg, progesterone; WM, whole mount.Page 13 of 16
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